The Rise of Direct-to-Patient Sales in Pharma: Navigating Cultural and Corporate Change
Executive Summary
The pharmaceutical sales industry is undergoing a monumental shift with the rise of direct-to-patient (DTP) sales. Recent shifts and recommendations at the federal level are opening doors to potentially lower costs and improve health in the US. This requires a fundamental shift in how pharma companies engage with patients. DTP is particularly transformative for high-demand medications that aren’t covered by insurance, as we have seen with GLP-1s, but already certain immunizations and other treatments are moving in this direction. This blog will focus on the cultural and corporate shifts that DTP sales entail. As the industry adapts to this direct-to-patient model, leaders must navigate new dynamics in customer engagement, technology, and corporate culture.
Building brand loyalty through influencers, ex: Nike Swoosh sunglasses concept by Graphic designer Davide Perella
Source: Facebook, @aurizn
Embracing Direct Customer Interaction
The shift to direct-to-patient sales means that pharmaceutical companies will no longer rely solely on pharmacy benefit managers and established supply chains. Instead, they’ll engage directly with patients, bringing about exciting new opportunities and some unique shifts in the market. Leaders need to shift focus towards creating brand loyalty, not B2B sales; this means building trust, demonstrating care for customers, and standing up excellent customer service. Building brand loyalty is critical, with more than 80% of consumers considering ”trust“ to be a deciding factor in their buying decisions. It’s a new marketing strategy, increasing brand recognition and knowledge through novel advertising channels. Imagine a world in which pharma companies have their own branded t-shirts or even get mentions in top 40 pop songs. This shift will require sales teams to master the art of customer engagement, personalized communication, and fostering a stronger connection between the brand and the patient.
Patient experience programs increase brand affiliation and loyalty.
Credit: etsy @wowhuateshow
Expansion of Patient Experience Programs
Outside of marketing, sales models need to adapt to DTP. Pharma companies can explore new approaches besides pay-per-dosage unit sales. Patient experience programs represent a wide range of tactics to increase retention of existing customers. Imagine opening a “welcome box” that includes a smart scale connected to a weight-tracking portal, a 6-month subscription to a weight loss mobile app, and a (company branded) wall calendar to make notes. Each of these are not only therapeutically valuable, but increase customer loyalty to the brand. Further programs might include loyalty discounts, partnership programs across industries, or bonuses or discounts at certain milestones. Just like “Kleenex” represents all tissue brands, we are beginning to see “Ozempic” represent all GLP-1s; we have seen the same with “Xanax” and “Adderall” in pockets. Marketing leaders need to start thinking about how their brand-name drug can become their own version of “Kleenex” for their class.
Technological Changes and Data Analytics
The move to direct-to-patient sales will necessitate a significant shift in technology as well. On the front end, companies will need patient-facing interfaces with modern user experiences that are intuitive and engaging. On the back end, there will be a heightened emphasis on data security, ensuring compliance with regulations like HIPAA and safeguarding personal health information. Additionally, the importance of data analytics will come to the forefront. According to the McKinsey Global Institute, “Data-driven organizations are 23 times more likely to acquire customers, six times as likely to retain customers, and 19 times as likely to be profitable as a result.” Leaders will need to track new metrics such as patient loyalty and engagement, as well as supply chain and regulatory metrics, and build new data pipelines and dashboards to answer questions from the C-suite about these new indicators.
Cultural Shift and Strategic Adaptation
The move to direct-to-patient sales also brings a major cultural shift for pharmaceutical companies. Leaders will need to prepare their teams, especially sales and marketing, for a new dynamic where the primary audience is the patient, not traditional health system stakeholders. This shift opens immense opportunities for deeper patient engagement but also brings challenges, such as heightened scrutiny and potential concerns about transparency and regulatory compliance. We are already seeing pushback and lawsuits; this type of attention can quickly erode customer trust if managed poorly. Leaders must drive a cultural change, increasing focus on patient loyalty and brand reputation; but cultural change is hard, and needs to be approached with intentionality and purpose. Leaders will need to navigate this new landscape carefully, ensuring that their strategies reflect the evolving expectations of patients and the broader healthcare market.
Looking ahead
As the pharmaceutical industry shifts towards direct-to-patient sales, leaders must embrace the cultural and strategic changes that come with it. This transformation presents exciting opportunities for deeper patient engagement, enhanced data-driven insights, and stronger brand loyalty. At Stone Transformation, we specialize in guiding organizations through these complex changes, ensuring that your teams are well-prepared and confident. We are transformation specialists, focusing on human side of change.
Embrace the future of pharma with us – contact Stone Transformation today and let us help you navigate this new phase in DTP sales.
